98%
921
2 minutes
20
The role of endothelin (ET)(A)-ET(B) receptor cross-talk in limiting the ET(A) receptor antagonist inhibition of ET-1 constriction is revealed by the partial or complete dependency of the ET(A) receptor antagonist inhibition on functional removal of the ET(B) receptor. Although functional removal of the ET(B) receptor is generally accomplished with ET(B) receptor antagonist, a novel approach using rats containing a naturally occurring deletion mutation in the ET(B) receptor [rescued "spotting lethal" (sl) rats; ET(B)(sl/sl)] demonstrated increased ET(A) receptor antagonist inhibition of ET-1 constriction in vena cava. We investigated whether this deletion mutation was also sufficient to remove the ET(B) receptor dependency of the ET(A) receptor antagonist inhibition of ET-1 constriction in the basilar artery. Consistent with previous reports, ET-1 plasma levels were elevated in ET(B)(sl/sl) as compared with ET(B)(+/+) rats. ET(B) receptor antagonist failed to relax the ET-1 constricted basilar artery from ET(B)(+/+) and ET(B)(sl/sl) rats. Relaxation to combined ET(A) and ET(B) receptor antagonist was greater than relaxation to ET(A) receptor antagonist in the basilar artery from ET(B)(+/+) and, unexpectedly, ET(B)(sl/sl) rats. These findings confirm the presence of ET(A)-ET(B) receptor cross-talk in the basilar artery. We speculate that mutant ET(B) receptor expression produced by alternative splicing may be sufficient to allow cross-talk.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/FJC.0000000000000335 | DOI Listing |
Nat Commun
September 2025
National Institute of Mental Health, Bethesda, MD, USA.
Inflammation is increasingly recognized as a risk factor for psychiatric disorders. Animal models of stress and stress-related disorders are associated with blood neutrophilia. The mechanistic relevance of this to symptoms or behavior is unclear.
View Article and Find Full Text PDFExpert Opin Pharmacother
August 2025
Department of Medicine, McGill University, Quebec, Canada.
Introduction: There has been a lack of novel medication classes approved for reducing blood pressure (BP) in hypertensive patients. Endothelins, powerful vasoconstricting peptides, have been at the forefront of experimental hypertension research since they were discovered in 1988. The recent PRECISION trial demonstrated the efficacy of aprocitentan, a novel endothelin receptor antagonist, in lowering blood pressure in patients with resistant hypertension (RH).
View Article and Find Full Text PDFCells
July 2025
Biomedical Engineering Department, Worcester Polytechnic Institute, Worcester, MA 01609, USA.
The endothelial glycocalyx (GCX) plays a crucial role in vascular health and integrity and influences many biochemical activities through mechanotransduction, in which heparan sulfate (HS) plays a major role. Endothelin-1 (ET-1) is a potent vasoregulator that binds to the endothelin B receptor (ETB) on endothelial cells (ECs), stimulating vasodilation, and to the endothelin A receptor on smooth muscle cells, stimulating vasoconstriction. While the shear stress (SS) dependence of ET-1 and HS is well documented, there is limited research documenting the SS dependence of the ETB.
View Article and Find Full Text PDFBiomed Pharmacother
August 2025
Biotech Research Institute, Grape King Bio Ltd., Long Tan Dist., Taoyuan City 325, Taiwan; Institute of BioPharmaceutical Science, National Sun Yat-sen University, Kaohsiung 804, Taiwan; Institute of Food Science and Technology, National Taiwan University, Taipei 106, Taiwan. Electronic address: gkb
Circulating tumor cells (CTCs) play a key role in cancer metastasis. However, the complex tumor microenvironment means that targeting these cells therapeutically remains a major clinical challenge. The natural compound GKB202, derived from the mycelium of Antrodia cinnamomea, has been shown to possess anti-cancer properties.
View Article and Find Full Text PDF